| Literature DB >> 24900722 |
Olivier Mirguet1, Stéphane Sautet1, Catherine-Anne Clément1, Jérôme Toum1, Frédéric Donche1, Celine Marques1, Emilie Rondet1, Mathieu Pizzonero1, Benjamin Beaufils1, Yann Dudit1, Pascal Huet1, Lionel Trottet1, Pascal Grondin1, Jean-Marie Brusq1, Eric Boursier1, Yannick Saintillan1, Edwige Nicodeme1.
Abstract
AMP-activated protein kinase (AMPK) is an evolutionarily conserved fuel-sensing enzyme that is activated in shortage of energy and suppressed in its surfeit. AMPK activation stimulates fatty acid oxidation, enhances insulin sensitivity, alleviates hyperglycemia and hyperlipidemia, and inhibits proinflammatory changes. Thus, AMPK is a well-received therapeutic target for type 2 diabetes and other metabolic disorders. Here, we will report the discovery of pyrrolopyridone derivatives as AMPK direct activators. We will illustrate the synthesis and structure-activity relationships of the series as well as some pharmacokinetic results. Some compounds exhibited encouraging oral exposure and were evaluated in a mouse diabetic model. Compound 17 showed oral activity at 30 mg/kg on blood glucose.Entities:
Keywords: AMPK direct activator; P-gp substrate; pyridone; type 2 diabetes
Year: 2013 PMID: 24900722 PMCID: PMC4027520 DOI: 10.1021/ml400157g
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345